Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 2948467, 12 pages
https://doi.org/10.1155/2017/2948467
Research Article

HPV16 E6 Promotes Breast Cancer Proliferation via Upregulation of COX-2 Expression

1Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453003, China
2The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China

Correspondence should be addressed to J. Cui; moc.931@10881528731 and X. L. Qian; moc.361@30iyaijgnaw

Received 6 April 2017; Revised 10 June 2017; Accepted 3 July 2017; Published 9 November 2017

Academic Editor: Myong Cheol Lim

Copyright © 2017 Y. X. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  2. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. G. Brody, R. A. Rudel, K. B. Michels et al., “Environmental pollutants, diet, physical activity, body size, and breast cancer: Where do we stand in research to identify opportunities for prevention?” Cancer, vol. 109, no. 12, pp. 2627–2634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kaiser, “Cholesterol forges link between obesity and breast cancer,” Science, vol. 342, no. 6162, p. 1028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Gage, D. Wattendorf, and L. R. Henry, “Translational advances regarding hereditary breast cancer syndromes,” Journal of Surgical Oncology, vol. 105, no. 5, pp. 444–451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Anothaisintawee, C. Wiratkapun, P. Lerdsitthichai et al., “Risk factors of breast cancer: a systematic review and meta-analysis,” Asia-Pacific Journal of Public Health, vol. 25, no. 5, pp. 368–387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. L. Glaser, A. J. Canchola, T. H. Keegan, C. A. Clarke, T. A. Longacre, and M. L. Gulley, “Variation in risk and outcomes of Epstein–Barr virus-associated breast cancer by epidemiologic characteristics and virus detection strategies: an exploratory study,” Cancer Causes & Control, vol. 28, no. 4, pp. 273–287, 2017. View at Publisher · View at Google Scholar
  8. H. Wu, C. Zhao, V. P. Adhikari, L. Lu et al., “The prevalence and clinicopathological features of breast cancer patients with hepatitis B virusinfection in China,” Oncotarget, 2017. View at Google Scholar
  9. N. E. Ilahi, S. Anwar, M. Noreen, S. N. Hashmi, and S. Murad, “Detection of human papillomavirus-16 DNA in archived clinical samples of breast and lung cancer patients from North Pakistan,” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 12, pp. 2497–2502, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Omura, M. K. Jones, A. Nihrane, H. Duvvi, Y. Shimotsuura, and M. Ohki, “More than 97% of human papilloma virus type 16 (hpv-16) was found with chrysotile asbestos & relatively smooth round tumor outline, and less than 3% was found with hpv-18 and tremolite asbestos & irregular sawtooth-like zigzag outline in breast cancer tissues in over 500 mammograms of female patients: their implications in diagnosis, treatment, and prevention of breast cancer,” Acupuncture and Electro-Therapeutics Research, vol. 38, no. 3-4, pp. 211–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Yin, D. Duluc, H. Joo, and et al, “Dendritic cell targeting vaccine for HPV-associated cancer,” Cancer Cell Microenviron, vol. 3, no. 4, 1482 pages, 2016. View at Publisher · View at Google Scholar
  12. K. K. Wu, “Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles,” Journal of Laboratory and Clinical Medicine, vol. 128, no. 3, pp. 242–245, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. R. E. Harris, B. C. Casto, and Z. M. Harris, “Cyclooxygenase-2 and the inflammogenesis of breast cancer,” World Journal of Clinical Oncology, vol. 5, no. 4, pp. 677–692, 2014. View at Publisher · View at Google Scholar
  14. L. Wang, S. Gao, W. Jiang et al., “Antioxidative dietary compounds modulate gene expression associated with apoptosis, DNA repair, inhibition of cell proliferation and migration,” International Journal of Molecular Sciences, vol. 15, no. 9, pp. 16226–16245, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Q. Zhao, J. Guo, G. Wang, Y. Chu, and X. Hu, “Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma,” Oncotarget, vol. 8, no. 1, pp. 1668–1677, 2017. View at Publisher · View at Google Scholar
  16. S. Tury, V. Becette, F. Assayag et al., “Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer,” Oncotarget, vol. 7, no. 51, pp. 85124–85141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Riva, M. De Dominici, I. Gnemmi et al., “Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2,” Oncotarget, vol. 7, no. 49, pp. 81555–81570, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Friedrichs, S. Gluba, H. Eidtmann, and W. Jonat, “Overexpression of p53 and prognosis in breast cancer,” Cancer, vol. 72, no. 12, pp. 3641–3647, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Band, S. Dalal, L. Delmolino, and E. J. Androphy, “Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells,” EMBO Journal, vol. 12, no. 5, pp. 1847–1852, 1993. View at Google Scholar · View at Scopus
  20. J.-M. Bae and E. H. Kim, “Human papillomavirus infection and risk of breast cancer: a meta-analysis of case-control studies,” Infectious Agents and Cancer, vol. 11, 14 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Wu, A. L. Abramson, M. J. Shikowitz, A. J. Dannenberg, and B. M. Steinberg, “Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas,” Clinical Cancer Research, vol. 11, no. 17, pp. 6155–6161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Subbaramaiah and A. J. Dannenberg, “Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange,” Cancer Research, vol. 67, no. 8, pp. 3976–3985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Obermajer, R. Muthuswamy, J. Lesnock, R. P. Edwards, and P. Kalinski, “Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells,” Blood, vol. 118, no. 20, pp. 5498–5505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg, “Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells,” Cancer Research, vol. 67, no. 9, pp. 4507–4513, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Campillo, M. Torres, A. Vilaseca et al., “Role of cyclooxygenase-2 on intermittent hypoxia-induced lung tumor malignancy in a mouse model of sleep apnea,” Scientific Reports, vol. 7, p. 44693, 2017. View at Publisher · View at Google Scholar
  26. H. Hsu, M. Chen, C. H. Day et al., “Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation,” World Journal of Gastroenterology, vol. 23, no. 7, p. 1171, 2017. View at Publisher · View at Google Scholar
  27. S. Shirali, A. Barari, SA. Hosseini et al., “Effects of six weeks endurance training and aloe vera supplementation on COX-2 and VEGF levels in mice with breast cancer,” Asian Pacific Journal of Cancer Prevention, vol. 18, no. 1, pp. 31–36, 2017. View at Google Scholar
  28. J. Sun, N. Liu, H. Zhuang, L. Zhao, Z. Yuan, and P. Wang, “Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell,” Cancer Biomarkers, vol. 19, no. 1, pp. 45–50, 2017. View at Publisher · View at Google Scholar
  29. W. L. Pridgen, C. Duffy, J. F. Gendreau, and R. M. Gendreau, “A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia,” Journal of Pain Research, vol. Volume 10, pp. 451–460, 2017. View at Publisher · View at Google Scholar
  30. B. Liu, S. Yan, L. Qu, and J. Zhu, “Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway,” Cancer Cell International, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  31. Q. Zhao, J. Guo, G. Wang, Y. Chu, and X. Hu, “Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma,” Oncotarget, vol. 8, no. 1, pp. 1668–1677, 2017. View at Publisher · View at Google Scholar
  32. Y.-X. Wang, J.-X. Gao, X.-Y. Wang, L. Zhang, and C.-M. Liu, “Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells,” Tumor Biology, vol. 33, no. 4, pp. 957–966, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Tong, B. Wei, S. Chen et al., “Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study,” Oncotarget, 2017. View at Publisher · View at Google Scholar
  34. R. Ghodsi, E. Azizi, and A. Zarghi, “Synthesis and biological evaluation of 4-(imidazolylmethyl)-2-(4-methylsulfonyl phenyl)-quinoline derivatives as selective COX-2 Inhibitors and in-vitro anti-breast cancer agents,” Iranian Journal of Pharmaceutical Research, vol. 15, no. 1, pp. 169–177, 2016. View at Publisher · View at Google Scholar
  35. W. Akhtar, G. Verma, M. F. Khan et al., “Synthesis of hybrids of dihydropyrimidine and pyridazinone as potential anti-breast cancer agents,” Mini-Reviews in Medicinal Chemistry, 2017. View at Google Scholar
  36. C. Bocca, F. Bozzo, A. Bassignana, and A. Miglietta, “Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines,” Molecular and Cellular Biochemistry, vol. 350, no. 1-2, pp. 59–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Yang, J. Jeang, K. Cheng et al., “Current state in the development of candidate therapeutic HPV vaccines,” Expert Review of Vaccines, vol. 15, no. 8, pp. 989–1007, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. D. A. Costa RMG, R. Araújo, J. M. O. Santos et al., “Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice,” Anticancer Research, vol. 37, no. 6, pp. 2913–2918, 2017. View at Google Scholar
  39. G. A. Alshafie, H. M. Abou-Issa, K. Seibert et al., “Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammarytumor model,” Oncology Reports, vol. 7, no. 6, pp. 1377–1381, 2000. View at Google Scholar
  40. C.-C. Lin, C.-M. Chan, Y.-P. Huang, S.-H. Hsu, C.-L. Huang, and S.-J. Tsai, “Methylglyoxal activates NF-κB nuclear translocation and induces COX-2 expression via a p38-dependent pathway in synovial cells,” Life Sciences, vol. 149, pp. 25–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Norouzi, M. Norouzi, M. Amini et al., “Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways,” DARU, Journal of Pharmaceutical Sciences, vol. 24, no. 1, article no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Yu, X. Li, L. Qu et al., “DXXK exerts anti-inflammatory effects by inhibiting the lipopolysaccharide-induced NF-κB/COX-2 signalling pathway and the expression of inflammatory mediators,” Journal of Ethnopharmacology, vol. 178, pp. 199–208, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Xu, R. A. Katzenellenbogen, C. Grandori, and D. A. Galloway, “NFX1 plays a role in human papillomavirus type 16 E6 activation of NFκB activity,” Journal of Virology, vol. 84, no. 21, pp. 11461–11469, 2010. View at Publisher · View at Google Scholar · View at Scopus